Conjunctival provocation testing: Overview of recent clinical trials in ocular allergy

Current Opinion in Allergy and Clinical Immunology

Volumn 2, Issue 5, 2002, Pages 413-417

  Friedlaender, Mitchell H ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

Allergic conjunctivitis; Conjunctival provocation test; Ocular allergy; Seasonal allergic conjunctivitis

Indexed keywords

ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZELASTINE; CETIRIZINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; KETOROLAC TROMETAMOL; LEVOCABASTINE; LODOXAMIDE; LORATADINE; N ACETYLASPARTYLGLUTAMIC ACID; NAPHAZOLINE; NEDOCROMIL; NONSTEROID ANTIINFLAMMATORY AGENT; OLOPATADINE; PHENIRAMINE; TERFENADINE; VASOCONSTRICTOR AGENT;

ALLERGIC CONJUNCTIVITIS; APPETITE DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; HUMAN; MAST CELL; MODEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; REVIEW; SEASONAL VARIATION; SIDE EFFECT; WEIGHT GAIN;

EID: 0036772451     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200210000-00008     Document Type: Review

References (78)

1. Blackley CH. Experimental researches on the cause and nature of catarrhous acativas. In: Hay Fever or Hay Asthma. London: Bailliere Tindal Cox Ltd.; 1873.
2. Noon L. Prophylactic inoculation against hay fever. Lancet 1911; 1:1572.
3. Peshkin MM. A dry pollen ophthalmic test in pollen asthma and hayfever patients negative to cutaneous tests. J Allergy 1931; 3:20-29.
4. Abram LE. An evaluation of conjunctival testing in extrinsic respiratory allergy. J Allergy 1949; 20:66-69.
5. Tuft L, Tornsey PJ, Ettelson LN, et al. Ophthalmic and nasal mucosal testing as an aid in the determination of house dust allergy. J Allergy 1962; 33:448-457.
6. Tuft L. The value of eye tests with inhalant allergens - A clinical study. Ann Allergy 1967; 25:183-191.
7. Ciprandi G, Buscaglia S, Scordamaglia A, et al. Allergen-specific conjunctival challenge in asthma. An additional diagnostic tool to define sensitization. Int Arch Allergy Immunol 1997; 112:247-250.
8. Moller C, Bjorksten B, Nilsson G, et al. The precision of the conjunctival provocation test. Allergy 1984; 39:37-41.
9. Friedlaender MH. Conjunctival provocation tests: A model of human ocular allergy. Trans Am Ophthalmol Soc 1989; 87:577-597.
10. Abelson M, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990; 108:84-88.
11. Bacon AS, Ahuluwalia P, Irani AM, et al. Tear and conjunctival changes during the allergen-induced early- and late-phase responses. J Allergy Clin Immunol 2000; 106:948-954.
12. Bonini S, Bonini S, Bucci MG, et al. Allergen dose response and late symptoms in a human model of ocular allergy. J Allergy Clin Immunol 1990; 86:869-876.
13. Allansmith MR, Baird RS, Greiner JV, et al. Late-phase reactions in ocular anaphylaxis in the rat. J Allergy Clin Immunol 1984; 76:49-55.
14. Bonini S, Trocme SD, Barney NP, et al. Late-phase reaction and tear fluid cytology in the rat ocular anaphylaxis. Curr Eye Res 1987; 6:659-665.
15. Calonge M, Briggs RM, Levene RB, et al. Early and late phases of ocular anaphylaxis in actively immunized guinea pigs. Acta Ophthalmol (Copenh) 1990; 68:470-476.
16. Leonardi A, Secchi AG, Briggs R, et al. Conjunctival mast cells and the allergic late phase reaction. Ophthal Res 1992; 24:234-242.
17. Proud D, Sweet J, Stein P, et al. Inflammatory mediator release on conjunctival provocation of allergic subjects with allergen. J Allergy Clin Immunol 1990; 85:896-905.
18. Karl O, Salo OP, Halmepuro L, et al. Tear histamine during allergic conjunctivitis challenge. Graefes Arch Clin Exp Ophthalmol 1985; 223:60-62.
19. Leonardi A, Borghesan F, Faggian D, et al. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. Am J Ophthalmol 2000; 129:151-158.
20. Woodward DF, Nieves AL, Hawley SB, et al. The pruritogenic and inflammatory effects of prostanoids in the conjunctiva. J Ocul Pharmacol Ther 1995; 11:339-347.
21. Margrini L, Bonini S, Centofanti M, et al. Tear tryptase levels and allergic conjunctivitis. Allergy 1996; 51:577-581.
22. Butrus S, Ochsner KI, Abelson M, et al. The level of tryptase in human tears. An indicator of activation of conjunctival mast cells. Ophthalmology 1990; 97:1678-1683.
23. Bonini S, Magrini L, Rotiroti G, et al. The eosinophil and the eye. Allergy 1997; 52:44-47.
24. Montan PG, van Hage-Hamsten M, Zetterstrom O. Sustained eosinophil cationic protein release into tears after a single high-dose conjunctival allergen challenge. Clin Exp Allergy 1996; 26:1125-1130.
25. Vesaluoma M, Rosenberg ME, Teppo A, et al. Tumour necrosis factor alpha (TNF alpha) in tears of atopic patients after conjunctival allergen challenge. Clin Exp Allergy 1999; 29:537-542.
26. Salonen EM, Lauharanta J, Sim PS, et al. Rapid appearance of plasmin in tear fluid after ocular allergen exposure. Clin Exp Immunol 1988; 73:146-148.
27. Anderson DF, MacLeod JD, Baddeley SM, et al. Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leucocyte infiltration. Clin Exp Allergy 1997; 27:1060-1066.
28. Bonini S, Bonini S, Vecchione A, et al. Inflammatory changes in conjunctival scrapings after allergen provocation in humans. J Allergy Clin Immunol 1990; 82:462-469.
29. Bagnasco M, Pesce G, Fiorino N, et al. In situ hybridization analysis of ICAM-1 (CD54) mRNA on conjunctival epithelium during allergic inflammation. Clin Exp Allergy 1997; 27:737-743.
30. Ciprandi G, Pronzato C, Ricca V, et al. Allergen-specific challenge induces intercellular adhesion molecule 1 (ICAM-1 or CD54) on nasal epithelial cells in allergic subjects. Relationships with early and late inflammatory phenomena. Am J Respir Crit Care Med 1994; 150:1653-1659.
31. Abelson MB, Paradis A, George MA, et al. Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis. Arch Ophthalmol 1990; 108:520-524.
32. Janssens M. Efficacy of levocabastine in conjunctival provocation studies. Doc Ophthalmol 1992; 82:341-351.
33. Hammann CP, Kammerer R, Gerber M, et al. Comparison of effects of topical levocabastine and nedocromil sodium on the early response in a conjunctival provocation test with allergen. J Allergy Clin Immunol 1996; 98:1045-1050.
34. Richard C, Trinquand C, Bloch-Michel E. Compsarison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Study Group. Eur J Ophthalmol 1998; 8:207-216.
35. 1 antagonist, in a conjunctival provocation test with allergen. J Allergy Clin Immunol 1988; 82:590-594.
36. Netland PA, Leahy C, Krenzer KL. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model. Am J Ophthalmol 2000; 130:717-723.
37. Discepola M, Deschenes J, Abelson M. Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis. Acta Ophthalmol Scand Suppl 1999; 228:43-46.
38. Discepola M, Deschenes J, Abelson M. ComparisDn of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis. Acta Ophthalmol Scand Suppl 1999; 228:43-46.
39. Ciprandi G, Buscaglia S, Pesce G, et al. Protective effect of loratadine on specific conjunctival provocation test. Int Arch Allergy Appl Immunol 1991; 96:344-347.
40. Ciprandi G, Buscaglia S, Marchesi E, et al. Protective effect of loratadine on late phase reaction induced by conjunctival provocation test. Int Arch Allergy Immunol 1993; 100:185-189.
41. Bousquet J, Chanel I, Czarlewski W, et al. Evaluation of a composite scoring system in conjunctival challenge with allergen: Reproducibility and evolution during loratadine treatment. Allergy 1995; 50:841-843.
42. Ciprandi G, Buscaglia S, Pronzato C, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1996; 95:612-621.
43. Ciprandi G, Buscaglia S, Iudice A, et al. Protective effect of different doses of terfenadine on the conjunctival provocation test. Allergy 1992; 47:309-312.
44. Leonardi A, Busato F, Fregona I, et al. Anti-inflammatory and antiallergic effects of ketorolac tromethamine in the conjunctival provocation model. Br J Ophthalmol 2000; 84:1228-1232.
45. Parys W, Blockhuys S, Janssens M. New trends in the treatment of allergic conjunctivitis. Doc Ophthalmol 1992; 82:353-360.
46. Bonini S, Schiavone M, Magrini L, et al. Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis. Ophthalmology 1997; 104:849-853.
47. Ciprandi G, Buscaglia S, Catrullo A, et al. Antiallergic activity of topical lodoxamide on in vivo and in vitro models. Allergy 1996; 51:946-951.
48. Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 1998; 81:211-218.
49. Deschenes J, Discepola M, Abelson M. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge protocol. Acta Ophthalmol Scand Suppl 1999; 228:47-52.
50. Butrus S, Greiner JV, Discepola M, et al. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther 2000; 22:1462-1470.
51. Abelson MB, Welch DL. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solutin 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand Suppl 2000; 230:60-63.
52. Cook EB, Stahl JL, Barney NP, et al. Olopatadine inhibits TNF-alpha release from human conjunctival mast cells. Ann Allergy Asthma Immunol 2000; 84:504-508.
53. Ahuluwalia P, Anderson DF, Wilson SJ, et al. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms. J Allergy Clin Immunol 2001; 108:449-454.
54. Friedlaender MH, Harris J, LaVallee N, et al. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model. Ophthalmology 2000; 107:2152-2157.
55. Horak F, Berger UE, Menapace R, et al. Dose-dependent protection by azelastine eye drops against pollen-induced allergic conjunctivitis. A doubleblind, placebo-controlled study. Arzneimittelforschung 1998; 48:379-384.
56. Ciprandi G, Buscaglia S, Catrullo A, et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin Exp Allergy 1996; 27:182-191.
57. Harper DG, Chen CE, Friedlaender MH. Controlled comparison of two fluorometholone formulations in the antigen challenge model of allergic conjunctivitis. Contact Lens Association of Ophthalmology Journal 1995; 21:256-260.
58. Giede-Tuch C, Westhoff M, Zarth A. Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. Allergy 1998; 53:857-862.
59. Sabbah A, Marzetto M. Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children. Curr Med Res Opin 1998; 14:161-170.
60. Abelson M, Howes J, George M. The conjunctival provocation test model of ocular allergy: Utility for assessment of an ocular corticosteroid, loteprednol etabonate. J Ocul Pharmacol Ther 1998; 14:533-542.
61. Abelson MB, Allansmith MR, Friedlaender MH. Effects of topically applied ocular decongestant and antihistamine. Am J Ophthalmol 1980; 90:254-257.
62. 1 antagonist in patients with allergic conjunctivitis. Allergy 1985; 40:491-496.
63. Foster CS. The Cromolyn Sodium Collaborative Study Group: Evaluation of topical cromolyn sodium in the treatment of vernal keratoconjunctivitis. Ophthalmology 1988; 95:194-201.
64. Duzman E, Warman A, Warman R. Efficacy and safety of topical oxymetazoline in treating allergic and environmental conjunctivitis. Ann Ophthalmol 1986; 18:28-31.
65. Ciprandi G, Cerqueti P, Sacca S, et al. Levocabastine versus cromolyn sodium in the treatment of pollen-induced conjunctivitis. Ann Allergy 1990; 65:156-158.
66. Janssens M. Levocabastine: A new topical approach for the treatment of paediatric allergic rhinoconjunctivitis. Rhinology-Suppl 1992; 13:39-49.
67. Abelson MB, Weintraub D. Levocabastine eye drops: A new approach for the treatment of acute allergic conjunctivitis. Eur J Ophthalmol 1994; 4:91-101.
68. Kray KT, Squire Jr EN, Tipton WR, et al. Cromolyn sodium in season allergic conjunctivitis. J Allergy Clin Immunol 1985; 76:623-627.
69. Ruggieri ML, Scorcia G. Double-blind group comparative trial of sodium cromoglycate eye ointment and placebo in the treatment of allergic eye diseases. Ann Allergy 1987; 58:109-112.
70. Foster CS. Evaluation of topical cromolyn sodium in the treatment of vernal keratoconjunctivitis. Ophthalmology 1988; 95:194-201.
71. Alexander M. Comparative therapeutic studies with Tilavist. Allergy 1995; 50:23-29.
72. Kjellman NI, Stevens MT. Clinical experience with Tilavist: An overview of efficacy and safety. Allergy 1995; 50:14-22.
73. Kjellman NI, Anderson B. Terfenadine reduces skin and conjunctival reactivity in grass pollen allergic children. Clin Allergy 1986; 16:441-449.
74. Vanden Bussche G, Emanuel MB, Rombaut N. Clinical profile of astemizole. A survey of 50 double-blind trials. Ann Allergy 1987; 58:184-188.
75. 1-blocking antihistamine. Critical review of pharmacological and clinical studies (in Italian). Minerva Medica 2002; 79:219-227.
76. Panayotopoulos SM, Panayotopoulou ES. Efficacy of cetirizine in the treatment of seasonal allergic rhinoconjunctivitis. Ann Allergy 1990; 65:146-148.
77. Schoeneich M, Pecoud AR. Effect of cetirizine in a conjunctival provocation test with allergens. Clin Exp Allergy 1990; 20:171-174.
78. Bonnet M, Ducournau D, Lumbroso P, et al. N-acetyl-aspartylglutamic acid eye drops in allergic-type conjunctivitis. Double-blind comparative clinical study. (in French). J Fr Ophthalmol 1985; 8:573-578.